Monitor for whether this is part of a pre-arranged 10b5-1 trading plan, common for executives to sell after option vesting. Given the coordinated timing and lack of purchases, this reflects routine portfolio management, not a negative signal. However, sustained selling in future periods could indicate weakening confidence.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $33.75entry
- T+1 · 9mo ago +0.24%α +0.69% · $33.83
- T+5 · 9mo ago −5.93%α −4.80% · $31.75
- T+20 · 8mo ago −11.82%α −5.42% · $29.76
- T+60 · 6mo ago +1.23%α −6.52% · $34.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Seven executives at Teva Pharmaceutical exercised stock options and sold shares in the open market on March 5, 2026, generating over $2.7M in aggregate proceeds. The transactions were primarily driven by option exercises followed by sales, with CEO Francis Richard D and multiple EVPs selling significant portions of their exercised shares. This is a routine insider disposition pattern, not indicative of distress or strong conviction.
Key Financial Metrics
Key Facts
- CEO Francis Richard D sold 20,025 shares for $634,160 after exercising 42,452 options (non-cash).
- Multiple EVPs (Fox, Daniell, Hughes, Shields, Jover, Savage) conducted similar exercise-and-sell transactions on the same day.
- Total open-market sales in the cluster: $2,766,108 across 7 insiders.
- All derivative exercises were at $0 cost, indicating pre-granted stock options.
- No open-market purchases observed; all transactions were sales or non-cash exercises.
Financial Impact
$2.77M in insider sales over one day
Risk Factors
- Perception of insider pessimism if selling continues beyond planned schedules.
- Potential dilution from exercised options, though offset by typical treasury share practices.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (20 trades, 7d window) | cluster-TEVA-1773087521251 |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers